Abstract
We investigated the association between seven polymorphisms in four candidate genes involved in vitamin D and androgen metabolism with early-onset prostate cancer (CaP) risk. The polymorphisms were genotyped in 288 UK males who were diagnosed with CaP at the age of 55 y or younger and up to 700 population-based controls. An additional 50 cases (not selected for age) and 76 controls were also genotyped. Short (⩽22 repeats) AR (CAG)n repeats were associated with a significantly reduced risk of early onset CaP (OR 0.68, 95% CI 0.50–0.91) compared with men with long (>22) repeats. Men homozygous for the leucine variant of SRD5A2 p.89V>L were also found to be at a significantly increased risk of CaP compared with men who were homozygous for the valine allele (OR 1.84, 95% CI 1.15–2.98). No associations were found with the AR (GGC)n, CYP17 Msp A1 I, VDR Taq I, SRD5A2 (TA)n and p.49A>T polymorphisms and CaP risk. These findings suggest that common polymorphisms in the AR and SRD5A2 genes may be associated with early-onset CaP in British men.
Similar content being viewed by others
References
Office for National Statistics. Mortality statistics: Cause (Series DH2) No. 29. http://www.statistics.gov.uk; 2002.
American Cancer Society. Cancer facts & figures 2004. http://www.cancer.org; 2004.
Breslow N et al. Latent carcinoma of prostate at autopsy in seven areas. The International Agency for Research on Cancer, Lyons, France. Int J Cancer 1977; 20: 680–688.
Shimizu H et al. Cancers of the prostate and breast among Japanese and white immigrants in Los Angeles County. Br J Cancer 1991; 63: 963–966.
Boring CC, Squires TS, Tong T, Montgomery S . Cancer statistics, 1994. CA Cancer J Clin 1994; 44: 7–26.
Steinberg GD et al. Family history and the risk of prostate cancer. Prostate 1990; 17: 337–347.
Spitz MR et al. Familial patterns of prostate cancer: a case–control analysis. J Urol 1991; 146: 1305–1307.
Carter BS et al. Hereditary prostate cancer: epidemiologic and clinical features. J Urol 1993; 150: 797–802.
Picado-Leonard J, Miller WL . Cloning and sequence of the human gene for P450c17 (steroid 17 alpha-hydroxylase/17,20 lyase): similarity with the gene for P450c21. DNA 1987; 6: 439–448.
Coffey DS. In: Lepor H, Lawson RK (eds). Prostate Diseases. W. B. Saunders, Philadelphia, 1993, pp 28–56.
di Salle E et al. PNU 157706, a novel dual type I and II 5alpha-reductase inhibitor. J Steroid Biochem Mol Biol 1998; 64: 179–186.
Lu S, Tsai SY, Tsai MJ . Regulation of androgen-dependent prostatic cancer cell growth: androgen regulation of CDK2, CDK4, and CKI p16 genes. Cancer Res 1997; 57: 4511–4516.
Peehl DM et al. Antiproliferative effects of 1,25-dihydroxyvitamin D3 on primary cultures of human prostatic cells. Cancer Res 1994; 54: 805–810.
Giovannucci E et al. The CAG repeat within the androgen receptor gene and its relationship to prostate cancer. Proc Natl Acad Sci USA 1997; 94: 3320–3323.
Hakimi JM et al. Androgen receptor variants with short glutamine or glycine repeats may identify unique subpopulations of men with prostate cancer. Clin Cancer Res 1997; 3: 1599–1608.
Ingles SA et al. Association of prostate cancer risk with genetic polymorphisms in vitamin D receptor and androgen receptor. J Natl Cancer Inst 1997; 89: 166–170.
Stanford JL et al. Polymorphic repeats in the androgen receptor gene: molecular markers of prostate cancer risk. Cancer Res 1997; 57: 1194–1198.
Ekman P et al. Links between genetic and environmental factors and prostate cancer risk. Prostate 1999; 39: 262–268.
Hsing AW et al. Polymorphic CAG and GGN repeat lengths in the androgen receptor gene and prostate cancer risk: a population-based case–control study in China. Cancer Res 2000; 60: 5111–5116.
Hardy DO et al. Androgen receptor CAG repeat lengths in prostate cancer: correlation with age of onset. J Clin Endocrinol Metab 1996; 81: 4400–4405.
Bratt O et al. CAG repeat length in the androgen receptor gene is related to age at diagnosis of prostate cancer and response to endocrine therapy, but not to prostate cancer risk. Br J Cancer 1999; 81: 672–676.
Irvine RA, Yu MC, Ross RK, Coetzee GA . The CAG and GGC microsatellites of the androgen receptor gene are in linkage disequilibrium in men with prostate cancer. Cancer Res 1995; 55: 1937–1940.
Edwards SM et al. Androgen receptor polymorphisms: association with prostate cancer risk, relapse and overall survival. Int J Cancer 1999; 84: 458–465.
Carey AH et al. Polycystic ovaries and premature male pattern baldness are associated with one allele of the steroid metabolism gene CYP17. Hum Mol Genet 1994; 3: 1873–1876.
Nedelcheva Kristensen V et al. CYP17 and breast cancer risk: the polymorphism in the 5′ flanking area of the gene does not influence binding to Sp-1. Cancer Res 1999; 59: 2825–2828.
Feigelson HS et al. A polymorphism in the CYP17 gene increases the risk of breast cancer. Cancer Res 1997; 57: 1063–1065.
Huang CS et al. Breast cancer risk associated with genotype polymorphism of the estrogen-metabolizing genes CYP17, CYP1A1, and COMT: a multigenic study on cancer susceptibility. Cancer Res 1999; 59: 4870–4875.
Lunn RM et al. Prostate cancer risk and polymorphism in 17 hydroxylase (CYP17) and steroid reductase (SRD5A2). Carcinogenesis 1999; 20: 1727–1731.
Gsur A et al. A polymorphism in the CYP17 gene is associated with prostate cancer risk. Int J Cancer 2000; 87: 434–437.
Davis DL, Russell DW . Unusual length polymorphism in human steroid 5 alpha-reductase type 2 gene (SRD5A2). Hum Mol Genet 1993; 2: 820.
Kantoff PW et al. A polymorphism of the 5 alpha-reductase gene and its association with prostate cancer: a case-control analysis. Cancer Epidemiol Biomarkers Prev 1997; 6: 189–192.
Hsing AW et al. Polymorphic markers in the SRD5A2 gene and prostate cancer risk: a population-based case-control study. Cancer Epidemiol Biomarkers Prev 2001; 10: 1077–1082.
Latil AG et al. Prostate carcinoma risk and allelic variants of genes involved in androgen biosynthesis and metabolism pathways. Cancer 2001; 92: 1130–1137.
Margiotti K et al. Evidence for an association between the SRD5A2 (type II steroid 5 alpha-reductase) locus and prostate cancer in Italian patients. Dis Markers 2000; 16: 147–150.
Makridakis NM et al. Association of mis-sense substitution in SRD5A2 gene with prostate cancer in African-American and Hispanic men in Los Angeles, USA. Lancet 1999; 354: 975–978.
Jaffe JM et al. Association of SRD5A2 genotype and pathological characteristics of prostate tumors. Cancer Res 2000; 60: 1626–1630.
Mononen N et al. A missense substitution A49T in the steroid 5-alpha-reductase gene (SRD5A2) is not associated with prostate cancer in Finland. Br J Cancer 2001; 84: 1344–1347.
Soderstrom T et al. 5alpha-reductase 2 polymorphisms as risk factors in prostate cancer. Pharmacogenetics 2002; 12: 307–312.
Makridakis N et al. A prevalent missense substitution that modulates activity of prostatic steroid 5alpha-reductase. Cancer Res 1997; 57: 1020–1022.
Febbo PG et al. The V89L polymorphism in the 5alpha-reductase type 2 gene and risk of prostate cancer. Cancer Res 1999; 59: 5878–5881.
Makridakis NM, di Salle E, Reichardt JK . Biochemical and pharmacogenetic dissection of human steroid 5alpha-reductase type II. Pharmacogenetics 2000; 10: 407–413.
Morrison NA et al. Contribution of trans-acting factor alleles to normal physiological variability: vitamin D receptor gene polymorphism and circulating osteocalcin. Proc Natl Acad Sci USA 1992; 89: 6665–6669.
Morrison NA et al. Prediction of bone density from vitamin D receptor alleles. Nature 1994; 367: 284–287.
Correa-Cerro L et al. Vitamin D receptor polymorphisms as markers in prostate cancer. Hum Genet 1999; 105: 281–287.
Blazer III DG et al. Vitamin D receptor polymorphisms and prostate cancer. Mol Carcinog 2000; 27: 18–23.
Taylor JA et al. Association of prostate cancer with vitamin D receptor gene polymorphism. Cancer Res 1996; 56: 4108–4110.
Ingles SA et al. Strength of linkage disequilibrium between two vitamin D receptor markers in five ethnic groups: implications for association studies. Cancer Epidemiol Biomarkers Prev 1997; 6: 93–98.
Ingles SA et al. Association of prostate cancer with vitamin D receptor haplotypes in African-Americans. Cancer Res 1998; 58: 1620–1623.
Eeles RA, Group, t. U. F. P. S. C.-o. & Collaborators, t. C. B. U. F. P. C. S. Genetic predisposition to prostate cancer. Prostate Cancer Prostatic Diseases 1999; 2: 9–15.
Popat S et al. Prevalence of the APC E1317Q variant in colorectal cancer patients. Cancer Lett 2000; 149: 203–206.
Allen NE, Forrest MS, Key TJ . The association between polymorphisms in the CYP17 and 5alpha-reductase(SRD5A2) genes and serum androgen concentrations in men. Cancer Epidemiol Biomarkers Prev 2001; 10: 185–189.
Key TJ et al. A case–control study of diet and prostate cancer. Br J Cancer 1997; 76: 678–687.
Sham PC, Curtis D . Monte Carlo tests for associations between disease and alleles at highly polymorphic loci. Ann Hum Genet 1995; 59: 97–105.
Rebbeck TR et al. Modification of BRCA1-associated breast cancer risk by the polymorphic androgen-receptor CAG repeat. Am J Hum Genet 1999; 64: 1371–1377.
Given HF et al. The androgen receptor exon 1 trinucleotide repeat does not act as a modifier of the age of presentation in breast cancer. Eur J Cancer 2000; 36: 533–534.
Ishikawa S, Soloway MS, Van der Zwaag R, Todd B . Prognostic factors in survival free of progression after androgen deprivation therapy for treatment of prostate cancer. J Urol 1989; 141: 1139–1142.
Prehn RT . On the prevention and therapy of prostate cancer by androgen administration. Cancer Res 1999; 59: 4161–4164.
Thompson IM et al. The influence of finasteride on the development of prostate cancer. N Engl J Med 2003; 349: 215–224.
Schatzl G et al. Serum androgen levels in men: impact of health status and age. Urology 2003; 61: 629–633.
Habuchi T et al. Increased risk of prostate cancer and benign prostatic hyperplasia associated with a CYP17 gene polymorphism with a gene dosage effect. Cancer Res 2000; 60: 5710–5713.
Wadelius M et al. Prostate cancer associated with CYP17 genotype. Pharmacogenetics 1999; 9: 635–639.
Gayther SA et al. The frequency of germ-line mutations in the breast cancer predisposition genes BRCA1 and BRCA2 in familial prostate cancer. The Cancer Research Campaign/British Prostate Group United Kingdom Familial Prostate Cancer Study Collaborators. Cancer Res 2000; 60: 4513–4518.
Carter HB et al. Longitudinal evaluation of prostate-specific antigen levels in men with and without prostate disease. JAMA 1992; 267: 2215–2220.
Author information
Authors and Affiliations
Consortia
Corresponding author
Additional information
Supplementary Information accompanies the paper on Prostate Cancer website (http://www.nature.com/PCAN).
Supplementary information
Rights and permissions
About this article
Cite this article
Forrest, M., Edwards, S., Houlston, R. et al. Association between hormonal genetic polymorphisms and early-onset prostate cancer. Prostate Cancer Prostatic Dis 8, 95–102 (2005). https://doi.org/10.1038/sj.pcan.4500785
Received:
Revised:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1038/sj.pcan.4500785
- Springer Nature Limited
Keywords
This article is cited by
-
Polymorphisms in XPC gene and risk for prostate cancer
Molecular Biology Reports (2019)
-
Quantitative Assessment of the Association Between CYP17 rs743572 Polymorphism and Prostate Cancer Risk
Cell Biochemistry and Biophysics (2015)
-
Steroid 5-alpha-reductase type 2 (SRD5A2) V89L and A49T polymorphisms and sporadic prostate cancer risk: a meta-analysis
Molecular Biology Reports (2013)
-
GGN repeat length and GGN/CAG haplotype variations in the androgen receptor gene and prostate cancer risk in south Indian men
Journal of Human Genetics (2006)